|Articles|June 21, 2023
AAV Manufacturing: The benefits of growing serum-free, suspension HEK293 cells in the scale-X™ fixed-bed bioreactor
Author(s)Univercells Technologies
In this study, HEK293F cells grown in scale-X bioreactor produce >3x higher AAV-2 vector, with 25-52% lower cost than the reference process.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy
2
Next-Generation Modalities Drive New Antibody Discovery
3
Green Chemistry’s Role in Advancing US Chemical Innovation
4
Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage with Strategic Automation (Part 2)
5